The Cannabinoid CB1 Receptor Antagonist,Rimonabant, as a Promising Pharmacotherapy for Alcohol Dependence: Preclinical Evidence |
| |
| Authors: | Giancarlo Colombo Alessandro Orrù Paola Lai Claudia Cabras Paola Maccioni Marina Rubio Gian Luigi Gessa Mauro A. M. Carai |
| |
| Affiliation: | (1) C.N.R. Institute of Neuroscience, Viale Diaz, 182, Cagliari (CA), 182 I-09126, Italy;(2) Department of Neuroscience, University of Cagliari, Cagliari, Italy;(3) Department of Biochemistry and Molecular Biology, Complutense University, Madrid, Spain |
| |
| Abstract: | Several lines of preclinical evidence indicate the ability of the prototypic cannabinoid CB1 receptor antagonist, rimonabant, to suppress various alcohol-related behaviors, including alcohol drinking and seeking behavior and alcohol self-administration in rats and mice. Together, these data—synthetically reviewed in the present paper—suggest (a) the involvement of the cannabinoid CB1 receptor in the neural substrate controlling alcohol intake, alcohol reinforcement, and the motivational properties of alcohol and (b) that rimonabant may constitute a new and potentially effective medication for the treatment of alcohol dependence. |
| |
| Keywords: | Cannabinoid CB1 receptor antagonist, rimonabant Alcohol Alcohol dependence (alcoholism) Alcohol drinking and seeking behavior Animal models of alcoholism |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
